VERA vs. ASND, CERE, ITCI, JAZZ, BPMC, VKTX, IONS, CYTK, SMMT, and OGN
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Summit Therapeutics (SMMT), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical preparations" industry.
Vera Therapeutics (NASDAQ:VERA) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
Vera Therapeutics currently has a consensus target price of $42.86, indicating a potential upside of 11.32%. Ascendis Pharma A/S has a consensus target price of $179.44, indicating a potential upside of 30.82%. Given Ascendis Pharma A/S's higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Vera Therapeutics.
In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Vera Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.11 beat Vera Therapeutics' score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.
Vera Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Vera Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Vera Therapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -152.68%. Vera Therapeutics' return on equity of -52.43% beat Ascendis Pharma A/S's return on equity.
99.2% of Vera Therapeutics shares are held by institutional investors. 21.7% of Vera Therapeutics shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Vera Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Ascendis Pharma A/S received 386 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 65.45% of users gave Ascendis Pharma A/S an outperform vote while only 55.56% of users gave Vera Therapeutics an outperform vote.
Summary
Vera Therapeutics and Ascendis Pharma A/S tied by winning 9 of the 18 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vera Therapeutics Competitors List
Related Companies and Tools
